Hypothalamic Amenorrhea
Conditions
Brief summary
The aim of our study is to investigate the effects of 6 months oh HRT on total anti-oxidant capacity, clinical, endocrine and metabolic features in women affected by hypotalamic amenorrhea. The study group included 20 patients treated with 1 mg of transdermal estradiol daily and 10mg of oral Medroxyprogesterone acetate from 16th to 24th day of therapy for six months. Menstrual pattern, anthropometric parameters, hormonal assays, DXA and bone metabolism parameters are evaluated before and after therapy.
Interventions
DRUG1 mg of transdermal estradiol daily and 10mg of oral MPA
Sponsors
Catholic University of the Sacred Heart
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Hypotalamic Amenorrhea
Exclusion criteria
* diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 gr oral glucose tolerance test) * hypertension * significant liver or renal impairment * other hormonal dysfunction (hypothalamic, pituitary, PCOS, thiroidal or adrenal) * neoplasms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Anti-oxidant Capacity | 6 Month |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bone Mineral Density | 6 Months | — |
| Osteocalcin | 6 Months | — |
| Estrogen levels | 6 Months | — |
| number of Cycles in 6 months | 6 Months | n° of menstrual cycle |
| beta crosslaps | 6 months | — |
Countries
Italy
Outcome results
None listed